Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The FDA has approved Kerendia® (finerenone) to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits.

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

New indication for Kerendia; investigational therapy shows promise for hypertension; Novolog interchangeable biosimilar gets approval; trial results for hormone-free contraceptive; Shingrix now ...

In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...

The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...

Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.